Anti-Phospholipase A2 Receptor Autoantibodies

Monalyn De Los Reyes Labitigan, Chaim Putterman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.

Original languageEnglish (US)
Title of host publicationAutoantibodies
Subtitle of host publicationThird Edition
PublisherElsevier B.V.
Pages545-552
Number of pages8
ISBN (Print)9780444563781
DOIs
StatePublished - Dec 1 2013

    Fingerprint

Keywords

  • Anti-phospholipase A2 receptor antibodies
  • Lupus nephritis
  • Membranous nephropathy
  • Phospholipase A2 receptor
  • Podocytes
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Labitigan, M. D. L. R., & Putterman, C. (2013). Anti-Phospholipase A2 Receptor Autoantibodies. In Autoantibodies: Third Edition (pp. 545-552). Elsevier B.V.. https://doi.org/10.1016/B978-0-444-56378-1.00064-2